Early Access Fsp1/s100a4 Polyclonal Antibody Massive 65% Savings [2i5EAobq]

Early Access Fsp1/s100a4 Polyclonal Antibody Massive 65% Savings [2i5EAobq]: Your Essential Research Tool

The Early Access Fsp1/s100a4 Polyclonal Antibody Massive 65% Savings [2i5EAobq] is a highly specialized research tool designed for researchers in the fields of cancer, cardiovascular, and signal transduction. This antibody offers exceptional specificity and sensitivity, making it an invaluable asset for various experimental applications. With its ability to recognize FSP1/S100A4 in human, mouse, and rat samples, this antibody is a versatile choice for your research needs.

• High specificity and sensitivity
• Recognizes FSP1/S100A4 in human, mouse, and rat samples
• Applications include WB and IHC

Product Specifications and Technical Details

The Early Access Fsp1/s100a4 Polyclonal Antibody Massive 65% Savings [2i5EAobq] is produced through affinity purification, ensuring a high level of purity and consistency. This antibody is conjugated with IgG, offering robust performance in various experimental settings. Key specifications include:

• Isotype: IgG
• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Applications: WB, IHC
• Immunogen: Recombinant fusion protein of human FSP1/S100A4

The antibody is supplied in a concentration of 1 mg/mL in a phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol, making it ready for immediate use in your experiments.

Applications and Benefits

The Early Access Fsp1/s100a4 Polyclonal Antibody Massive 65% Savings [2i5EAobq] is a powerful tool for studying the role of FSP1/S100A4 in various biological processes, including motility, invasion, and tubulin polymerization. This antibody is particularly useful for researchers investigating tumor metastasis and related diseases. Its practical applications include:

• Western blot (WB)
• Immunohistochemistry (IHC)

By using this antibody, researchers can gain valuable insights into the functions and interactions of FSP1/S100A4, contributing to advancements in cancer, cardiovascular, and signal transduction research. The Early Access Fsp1/s100a4 Polyclonal Antibody Massive 65% Savings [2i5EAobq] is a must-have for any laboratory focused on these critical areas of study.